Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Large Growth in Short Interest

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 52,800 shares, an increase of 58.6% from the February 28th total of 33,300 shares. Based on an average daily volume of 123,500 shares, the days-to-cover ratio is currently 0.4 days. Approximately 0.0% of the shares of the stock are sold short.

Shionogi & Co., Ltd. Trading Down 0.9 %

SGIOY stock traded down $0.07 during trading on Monday, reaching $7.59. 44,701 shares of the stock were exchanged, compared to its average volume of 134,492. The firm has a market capitalization of $12.91 billion, a price-to-earnings ratio of 13.06, a P/E/G ratio of 2.37 and a beta of 0.23. The company has a current ratio of 7.64, a quick ratio of 7.01 and a debt-to-equity ratio of 0.01. The business has a 50 day moving average price of $7.41 and a 200-day moving average price of $7.53. Shionogi & Co., Ltd. has a 1 year low of $6.22 and a 1 year high of $8.59.

Shionogi & Co., Ltd. (OTCMKTS:SGIOY) last posted its earnings results on Friday, January 31st. The company reported $0.16 earnings per share (EPS) for the quarter. Shionogi & Co., Ltd. had a return on equity of 12.02% and a net margin of 35.53%. On average, research analysts predict that Shionogi & Co., Ltd. will post 0.66 earnings per share for the current year.

Shionogi & Co., Ltd. Company Profile

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.